TransMedics Group, Inc.

TMDXNASDAQHealthcareMedical Devices

$70.78- (-)1Y −34.95%

As of Oct 16, 2026 close

Market cap: $3.12B
P/E (TTM): 20.53
Forward P/E: 10.00
Dividend yield: -
52-week range: $60.11$156.00
Volume (live): -
Avg. volume (3M): 791.99K

TransMedics Group, Inc. (TMDX) Analyst Forecast

Analyst consensus ratings, 12-month price targets, and expert recommendations for TransMedics Group, Inc. stock.

Analyst Consensus Rating

Investment consensus from 13 professional research analysts

Consensus Rating

Buy

Based on 13 unique analysts

(14 total ratings in last 90 days)

High Confidence3.5:1 Buy/Sell

Average Price Target

$97.56

+37.84% upside

Loading chart...

Strong Sell

Sell

Hold

Buy

Strong Buy

Latest TMDX Analyst Ratings & Recommendations

Recent analyst recommendations with rating changes and price target updates (last 90 days)

Date	Analyst	Firm	Action	Rating	Price Target
Oct 6, 2026	Unknown Analyst	Barclays	Initiates	Buy	$120.00
Oct 5, 2026	Matthew O'Brien	Piper Sandler	Maintains	Buy	$100.00
Oct 2, 2026	Ryan Daniels	William Blair	Maintains	Buy	-
Oct 2, 2026	Josh Jennings	TD Cowen	Maintains	Buy	$120.00
Sep 22, 2026	Michael Matson	Needham	Reiterates	Buy	$106.00
Sep 11, 2026	Thomas Stephan	Stifel Nicolaus	Maintains	Hold	$65.00
Sep 11, 2026	William Plovanic	Canaccord Genuity	Maintains	Buy	$95.00
Sep 4, 2026	Harshit Gupta	Zacks Equity Research	Initiates Coverage	Sell	-
Aug 24, 2026	Suraj Kalia	Oppenheimer	Maintains	Hold	-
Aug 7, 2026	Allen Gong	JP Morgan	Maintains	Hold	$73.00
Aug 6, 2026	Allen Gong	JP Morgan	Maintains	Hold	$73.00
Aug 5, 2026	Patrick Wood	UBS	Initiates Coverage	Hold	$80.00 → $77.00 −3.00 (−3.8%)
Aug 5, 2026	David Rescott	Baird	Maintains	Buy	$120.00 → $122.00 +2.00 (+1.7%)
Aug 4, 2026	Zacks Equity Research	Zacks Equity Research	Initiates Coverage	Sell	-

Unknown Analyst

Barclays

BuyInitiates

$120.00

Oct 6

Matthew O'Brien

Piper Sandler

BuyMaintains

$100.00

Oct 5

Ryan Daniels

William Blair

BuyMaintains

Oct 2

Josh Jennings

TD Cowen

BuyMaintains

$120.00

Oct 2

Michael Matson

Needham

BuyReiterates

$106.00

Sep 22

Thomas Stephan

Stifel Nicolaus

HoldMaintains

$65.00

Sep 11

William Plovanic

Canaccord Genuity

BuyMaintains

$95.00

Sep 11

Harshit Gupta

Zacks Equity Research

SellInitiates Coverage

Sep 4

Suraj Kalia

Oppenheimer

HoldMaintains

Aug 24

Allen Gong

JP Morgan

HoldMaintains

$73.00

Aug 7

Allen Gong

JP Morgan

HoldMaintains

$73.00

Aug 6

Patrick Wood

UBS

HoldInitiates Coverage

$80.00 → $77.00

Aug 5

David Rescott

Baird

BuyMaintains

$120.00 → $122.00

Aug 5

Zacks Equity Research

SellInitiates Coverage

Aug 4

Source: Professional analyst ratings and price targets from the last 90 days. Data as of Oct 6, 2026. Data sources and methodology

Frequently Asked Questions

What is the analyst consensus rating for TMDX?

The analyst consensus rating for TMDX is Buy, based on the latest ratings from 13 analysts over the last 90 days.

What is the average price target for TMDX?

The average 12-month price target for TMDX is $97.56, representing an upside of 37.8% from the Oct 16, 2026 close of $70.78.

What do analyst ratings mean?

Analyst ratings indicate investment recommendations: Strong Buy and Buy are bullish signals suggesting the stock may outperform. Hold means the stock is fairly valued. Sell and Strong Sell are bearish signals suggesting potential underperformance. These ratings are based on fundamental analysis and valuation models.

What is a price target?

A price target is an analyst's projection of a stock's fair value over a specific timeframe, typically 12 months. Analysts use fundamental analysis, financial modeling, and industry comparisons to estimate where the stock should trade. Price targets can range from low (conservative) to high (optimistic) estimates.